2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-145905
    D4R antagonist-1 2846077-19-6 98%
    D4R antagonist-1 is a potent and selective D4R antagonist with an IC50 of 6.87 µM. D4R antagonist-1 has the potential for the research of Parkinson’s disease.
    D4R antagonist-1
  • HY-145906
    D4R antagonis-2 2846077-70-9 98%
    D4R antagonist-2 is a potent and selective D4R antagonist with an IC50 of 6.52 µM. D4R antagonist-2 displays very favorable in vitro PK parameters and has good brain penetration. D4R antagonist-2 has the potential for the research of Parkinson’s disease.
    D4R antagonis-2
  • HY-145910
    NLRP3-IN-6 98%
    NLRP3-IN-6 (Compound 34) is a selective NLRP3 inflammasome inhibitor.
    NLRP3-IN-6
  • HY-145911
    NLRP3-IN-7 98%
    NLRP3-IN-7 (Compound 36) is a selective NLRP3 inflammasome inhibitor. NLRP3-IN-7 effectively blocks the assembly of the NLRP3 inflammasome.
    NLRP3-IN-7
  • HY-145945
    MAGL-IN-6 2414320-29-7 98%
    MAGL-IN-6 is a potent MAGL inhibitor with an IC50 of 4.71 nM. MAGL-IN-6 can be used for neurological disorders research (WO2020065613A1; example 234).
    MAGL-IN-6
  • HY-145959
    AMPA receptor antagonist-3 923272-18-8 98%
    AMPA receptor antagonist-3 is an AMPA receptor antagonist extracted from patent US20070027143A1. AMPA receptor antagonist-3 can be used for the research of central nervous system disorders.
    AMPA receptor antagonist-3
  • HY-146032
    p38-α MAPK-IN-4 2396754-57-5 98%
    p38-α MAPK-IN-4 (Compound 69) is a selective p38α MAPK inhibitor with an IC50 of 1.5 µM. p38-α MAPK-IN-4 rapidly and strongly prevents the development of mechanical allodynia (MA) in vivo.
    p38-α MAPK-IN-4
  • HY-146035
    AChE-IN-14 2390042-05-2 98%
    AChE-IN-14 (compound 5) is a potent cholinesterase inhibitor with IC50s of 0.46 , 0.48, and 0.44 μM for electric eel acetylcholinesterase (eeAChE), human recombinant acetylcholinesterase (hAChE), and equine serum butyrylcholinesterase (eqBuChE), respectively. AChE-IN-14 exhibits high affinity toward human H3 receptor (H3R; Ki= 159.8 nM). AChE-IN-14 can be used for the research of Alzheimer’s disease.
    AChE-IN-14
  • HY-146039
    AChE-IN-15 2242792-25-0 98%
    AChE-IN-15 (Compound 3d) is a reversible human acetylcholinesterase (huAChE) (IC50=6.8 μM) and human butyrylcholinesterase (huBChE) (IC50=16.1 μM) inhibitor. AChE-IN-15 shows significant antioxidant potency, AChE-IN-15 can be used for the research of Alzheimer’s disease.
    AChE-IN-15
  • HY-146068
    AEP-IN-1 3032742-75-6 98%
    AEP-IN-1 (Compound 13e) is a CNS agent-like non-covalent inhibitor of asparagine endopeptidase (AEP), with the IC50 of 89 nM. AEP-IN-1 can be used for the research of numerous neurological diseases such as Alzheimer’s disease (AD).
    AEP-IN-1
  • HY-146076
    5-HT6/5-HT2A receptor ligand-1 2411088-07-6 98%
    5-HT6/5-HT2A receptor ligand-1 (compound 33) is a dual 5-HT6/5-HT2A receptor antagonist, with a Ki of 2 nM and 11 nM, respectively. 5-HT6/5-HT2A receptor ligand-1 has the potential for neurological and psychiatric disorders research.
    5-HT6/5-HT2A receptor ligand-1
  • HY-146077
    5-HT6/5-HT2A receptor ligand-2 2411088-16-7 98%
    5-HT6/5-HT2A receptor ligand-2 (compound 42) is a brain-penetrant dual 5-HT6/5-HT2A receptor antagonist, with a Ki of 25 nM and 32 nM, respectively. 5-HT6/5-HT2A receptor ligand-2 shows pro-cognitive properties.
    5-HT6/5-HT2A receptor ligand-2
  • HY-146099
    GABAA receptor agent 7 2376841-18-6 98%
    GABAA receptor agent 7 (compoud 5c) is a potent GABAA receptor positive modulator. GABAA receptor agent 7 shows anticonvulsant activity in vitro and in vivo with low neurotoxicity. GABAA receptor agent 7 has the potential for the research of epilepsy.
    GABAA receptor agent 7
  • HY-146100
    GABAA receptor agent 8 2376841-54-0 98%
    GABAA receptor agent 8 (compoud 5e) is a potent GABAA receptor positive modulator. GABAA receptor agent 8 shows anticonvulsant activity in vitro and in vivo with low neurotoxicity. GABAA receptor agent 8 has the potential for the research of epilepsy.
    GABAA receptor agent 8
  • HY-146101
    NMDA receptor antagonist 5 2415998-36-4 98%
    NMDA receptor antagonist 5 (Compound 10e) is a potent, brain permeable and non-toxic NMDA receptor antagonist. NMDA receptor antagonist 5 can be used for neurological disorder research.
    NMDA receptor antagonist 5
  • HY-146135
    Tau-aggregation-IN-1 1619269-19-0 98%
    Tau-aggregation-IN-1 (Compound D-519) is a tau441 protein aggregation inhibitor with an IC50 of 21 µM. Tau-aggregation-IN-1 is also a dopamine D2 and D3 receptor agonist.
    Tau-aggregation-IN-1
  • HY-146137
    Transthyretin-IN-1 98%
    Transthyretin-IN-1 (Compound 1d) is a transthyretin (TTR) fibril formation inhibitor. Transthyretin-IN-1 can be used for Alzheimer’s disease research.
    Transthyretin-IN-1
  • HY-146139
    Aβ-IN-3 2477606-87-2 98%
    Aβ-IN-3 (compound 1) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-3 inhibits Aβ42 aggregation. However, Aβ-IN-3 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-3 can not change the aggregation state of Aβ42 into a nontoxic one.
    Aβ-IN-3
  • HY-146140
    Aβ-IN-4 2477606-97-4 98%
    Aβ-IN-4 (compound 12) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-4 inhibits Aβ42 aggregation. However, Aβ-IN-4 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-4 can not change the aggregation state of Aβ42 into a nontoxic one.
    Aβ-IN-4
  • HY-146142
    AChE/BuChE-IN-2 1946008-31-6 98%
    AChE/BuChE-IN-2 (Compound 5f) is an orally active AChE and BuChE inhibitor with IC50 values of 0.72 μM and 0.16 μM, respectively. AChE/BuChE-IN-2 shows a non-competitive inhibition with AChE and shows potent self-induced β-amyloid (Aβ) aggregation inhibition with an IC50 of 62.52 μM. AChE/BuChE-IN-2 can cross the BBB.
    AChE/BuChE-IN-2
Cat. No. Product Name / Synonyms Application Reactivity